Stay updated with breaking news from Their Ability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Children's Food and Beverage Market: Trends and Opportunities" report has been added to ResearchAndMarkets.com's offering. In 2020 and...
Teva Pharmaceuticals Europe BV has confirmed that the SmPC for COPAXONE® (Glatiramer Acetate (GA) injection) 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated.
Change to COPAXONE(Glatiramer Acetate (GA)) Summary of Product Characteristics (SmPC) in breastfeeding is relevant for the Multiple Sclerosis ("MS") community and provides information for neurologists
© Provided by Xinhua The drill was aimed at checking the alert posture of the combatants of the regiment and bolstering their ability of discharging fi
Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution thanks to the discovery of crucial pathogenetic mechanisms. CLL is still an incurable disease due to intrinsic or acquired resistance of the leukemic clone. Venetoclax is a Bcl-2 inhibitor with a marked activity in CLL, but emerging patterns of resistance are being described. We hypothesize that intrinsic features of CLL cells may contribute to drive mechanisms of resistance to venetoclax. We analyzed the expression of IRF4, Notch2 and Mcl-1 in a cohort of CLL patients. We evaluated CLL cells viability after genetic and p...